Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 8/20 | 0.44 |
| ▸ | ACACA | Q13085 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24000748 | 0.79 | CKS1B (0.55) | CKS1BSKP1SKP2DRD2SUV39H2 | |
| SCHEMBL2385473 | 0.78 | CKS1B (0.49) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL25546708 | 0.78 | ACACB (0.48) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL12082925 | 0.76 | CKS1B (0.54) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL12082500 | 0.76 | CKS1B (0.54) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL25548557 | 0.76 | SUV39H2 (0.50) | CKS1BSKP1SKP2DRD2SUV39H2 | |
| SCHEMBL12083122 | 0.76 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL12082503 | 0.76 | CKS1B (0.55) | CKS1BSKP1SKP2DRD2SIRT2 | |
| SCHEMBL38666500 | 0.75 | CKS1B (0.63) | CKS1BSKP1SKP2DRD2SUV39H2 | |
| SCHEMBL6066711 | 0.74 | CKS1B (0.56) | CKS1BSKP1SKP2DRD2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | CKS1B 192/4885SKP1 918/4885SKP2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.